Heatwurx (NASDAQ:PCSA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Heatwurx (NASDAQ:PCSA) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Heatwurx in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $25.00.

Heatwurx Stock Up 10.2%

NASDAQ:PCSA opened at $3.23 on Friday. The stock has a market cap of $7.33 million, a P/E ratio of -0.10 and a beta of 1.13. The business’s 50-day moving average price is $6.20 and its two-hundred day moving average price is $6.04. Heatwurx has a twelve month low of $2.74 and a twelve month high of $27.00.

Heatwurx (NASDAQ:PCSA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($1.75) EPS for the quarter, topping the consensus estimate of ($2.00) by $0.25. On average, equities research analysts expect that Heatwurx will post -4.05 EPS for the current fiscal year.

About Heatwurx

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.